Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2019
October 08, 2019 at 04:31 pm EDT
Share
Sangui Biotech International, Inc. announced earnings results for the full year ended June 30, 2019. For the full year, the company announced operating loss was USD 337,635 compared to USD 208,045 a year ago. Net loss was USD 323,576 compared to USD 201,810 a year ago.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
